Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
CANCER:
Peripheral T-cell Lymphoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Non-Hodgkin’s Lymphoma (831
)
Diffuse Large B Cell Lymphoma (295
)
Mantle Cell Lymphoma (101
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
Non-Hodgkin’s Lymphoma (831
)
Diffuse Large B Cell Lymphoma (295
)
Mantle Cell Lymphoma (101
)
Small Lymphocytic Lymphoma (98
)
T Cell Non-Hodgkin Lymphoma (79
)
Follicular Lymphoma (73
)
Lymphoplasmacytic Lymphoma (58
)
Marginal Zone Lymphoma (33
)
Burkitt Lymphoma (18
)
Cutaneous T-cell Lymphoma (12
)
Mediastinal B Cell Lymphoma (8
)
›
Associations
(48)
Heatmap
News
Twitter
Trials
Reset Filters
Veri cancer hierarchy
x
x
x
x
TNFRSF8 expression
Peripheral T-cell Lymphoma
TNFRSF8 expression
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
belinostat
Sensitive: A1 - Approval
belinostat
Sensitive
:
A1
belinostat
Sensitive: A1 - Approval
belinostat
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
pralatrexate
Sensitive: A1 - Approval
pralatrexate
Sensitive
:
A1
pralatrexate
Sensitive: A1 - Approval
pralatrexate
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
brentuximab vedotin
Sensitive: A1 - Approval
brentuximab vedotin
Sensitive
:
A1
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
denileukin diftitox
Sensitive: A1 - Approval
denileukin diftitox
Sensitive
:
A1
ALK positive
Peripheral T-cell Lymphoma
ALK positive
Peripheral T-cell Lymphoma
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
crizotinib
Sensitive: A2 - Guideline
crizotinib
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
etoposide IV
Sensitive: A2 - Guideline
etoposide IV
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
cyclophosphamide + etoposide IV
Sensitive
:
A2
cyclophosphamide + etoposide IV
Sensitive: A2 - Guideline
cyclophosphamide + etoposide IV
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
bortezomib
Sensitive: A2 - Guideline
bortezomib
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
bendamustine
Sensitive: A2 - Guideline
bendamustine
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
alemtuzumab
Sensitive: A2 - Guideline
alemtuzumab
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
lenalidomide
Sensitive: A2 - Guideline
lenalidomide
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
gemcitabine
Sensitive: A2 - Guideline
gemcitabine
Sensitive
:
A2
TNFRSF8 positive
Peripheral T-cell Lymphoma
TNFRSF8 positive
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: A2 - Guideline
brentuximab vedotin
Sensitive
:
A2
brentuximab vedotin
Sensitive: A2 - Guideline
brentuximab vedotin
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
EPOCH
Sensitive: A2 - Guideline
EPOCH
Sensitive
:
A2
EPOCH
Sensitive: A2 - Guideline
EPOCH
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
duvelisib
Sensitive: A2 - Guideline
duvelisib
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
DHAX
Sensitive: A2 - Guideline
DHAX
Sensitive
:
A2
DHAX
Sensitive: A2 - Guideline
DHAX
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
DHAP
Sensitive: A2 - Guideline
DHAP
Sensitive
:
A2
DHAP
Sensitive: A2 - Guideline
DHAP
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
cyclosporine
Sensitive: A2 - Guideline
cyclosporine
Sensitive
:
A2
cyclosporine
Sensitive: A2 - Guideline
cyclosporine
Sensitive
:
A2
ALK positive
Peripheral T-cell Lymphoma
ALK positive
Peripheral T-cell Lymphoma
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
alectinib
Sensitive: A2 - Guideline
alectinib
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
romidepsin
Sensitive: A2 - Guideline
romidepsin
Sensitive
:
A2
romidepsin
Sensitive: A2 - Guideline
romidepsin
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
ICE
Sensitive: A2 - Guideline
ICE
Sensitive
:
A2
ICE
Sensitive: A2 - Guideline
ICE
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
GemOx
Sensitive: A2 - Guideline
GemOx
Sensitive
:
A2
GemOx
Sensitive: A2 - Guideline
GemOx
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
GDP
Sensitive: A2 - Guideline
GDP
Sensitive
:
A2
GDP
Sensitive: A2 - Guideline
GDP
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
GVD
Sensitive: A2 - Guideline
GVD
Sensitive
:
A2
GVD
Sensitive: A2 - Guideline
GVD
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
ESHAP
Sensitive: A2 - Guideline
ESHAP
Sensitive
:
A2
ESHAP
Sensitive: A2 - Guideline
ESHAP
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
RP6530
Sensitive: B - Late Trials
RP6530
Sensitive
:
B
RP6530
Sensitive: B - Late Trials
RP6530
Sensitive
:
B
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
DZD4205
Sensitive: B - Late Trials
DZD4205
Sensitive
:
B
DZD4205
Sensitive: B - Late Trials
DZD4205
Sensitive
:
B
IL2RA expression
Peripheral T-cell Lymphoma
IL2RA expression
Peripheral T-cell Lymphoma
denileukin diftitox
Sensitive: C1 - Off-label
denileukin diftitox
Sensitive
:
C1
denileukin diftitox
Sensitive: C1 - Off-label
denileukin diftitox
Sensitive
:
C1
PD-L1 overexpression
Peripheral T-cell Lymphoma
PD-L1 overexpression
Peripheral T-cell Lymphoma
GB226
Sensitive: C3 – Early Trials
GB226
Sensitive
:
C3
GB226
Sensitive: C3 – Early Trials
GB226
Sensitive
:
C3
PD-1 overexpression
Peripheral T-cell Lymphoma
PD-1 overexpression
Peripheral T-cell Lymphoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
